DeepMed Research

ZEALAND PHARMA AS

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: -

Established: 1998-01-01

Employees: 150

Market Cap: $9.1B

Website: https://www.zealandpharma.com/

Clinical Trials

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Phase 2

Recruiting

Conditions: Overweight
Type 2 Diabetes
Obesity

Interventions: Drug: Petrelintide
Other: Placebo

First Posted Date: 2025-04-15

Last Posted Date: 2025-05-21

Lead Sponsor: Zealand Pharma

Target Recruit Count: 216

Registration Number: NCT06926842

Locations: 🇺🇸
Cullman Clinical Trials - Family Medicine, Cullman, Alabama, United States
🇺🇸
Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸
Medical Investigation Inc, Little Rock, Arkansas, United States

and more 22 locations

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

Phase 1

Completed

Conditions: Overweight and Obesity

Interventions: Drug: Dapiglutide 7.5 mg

First Posted Date: 2025-01-06

Last Posted Date: 2025-05-06

Lead Sponsor: Zealand Pharma

Target Recruit Count: 30

Registration Number: NCT06758583

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany

A Research Study Looking at the Safety of Single Doses of ZP9830 and How it Works in the Body of Healthy Participants

Phase 1

Recruiting

Conditions: Autoimmune Diseases

Interventions: Drug: ZP9830
Drug: Placebo

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-14

Lead Sponsor: Zealand Pharma

Target Recruit Count: 92

Registration Number: NCT06682975

Locations: 🇳🇱
Centre for Human Drug Research, Leiden, CL, Netherlands

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

Phase 2

Active, not recruiting

Conditions: Obesity

Interventions: Drug: Petrelintide
Drug: Placebo

First Posted Date: 2024-10-29

Last Posted Date: 2025-05-11

Lead Sponsor: Zealand Pharma

Target Recruit Count: 494

Registration Number: NCT06662539

Locations: 🇺🇸
Clinical Research Center of Florida, Pompano Beach, Florida, United States
🇺🇸
Palm Beach Research Center, West Palm Beach, Florida, United States
🇺🇸
Great Lakes Clinical Trials LLC dba Flourish Research, Chicago, Illinois, United States

and more 29 locations

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Phase 1

Terminated

Conditions: Safety and Tolerability

Interventions: Drug: ZP7570
Drug: Placebo

First Posted Date: 2023-08-21

Last Posted Date: 2025-04-25

Lead Sponsor: Zealand Pharma

Target Recruit Count: 84

Registration Number: NCT06000891

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

Phase 1

Completed

Conditions: Overweight
Healthy Volunteers
Obese

Interventions: Drug: ZP8396

First Posted Date: 2022-11-14

Last Posted Date: 2024-06-18

Lead Sponsor: Zealand Pharma

Target Recruit Count: 68

Registration Number: NCT05613387

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Phase 3

Recruiting

Conditions: Type 1 Diabetes
Hypoglycemia

Interventions: Drug: Dasiglucagon

First Posted Date: 2022-05-18

Last Posted Date: 2024-08-29

Lead Sponsor: Zealand Pharma

Target Recruit Count: 8

Registration Number: NCT05378672

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Indiana University School of Medicine, Indianapolis, Indiana, United States
🇺🇸
Cook Childrens Health Care System, Fort Worth, Texas, United States

and more 1 locations

A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants

Phase 1

Completed

Conditions: Healthy Volunteers
Overweight

Interventions: Drug: ZP8396
Drug: Placebo (ZP8396)

First Posted Date: 2021-10-27

Last Posted Date: 2023-01-17

Lead Sponsor: Zealand Pharma

Target Recruit Count: 64

Registration Number: NCT05096598

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, North Rhine-Westphalia, Germany

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

Phase 3

Completed

Conditions: Short Bowel Syndrome

Interventions: Drug: Glepaglutide

First Posted Date: 2021-08-05

Last Posted Date: 2024-11-22

Lead Sponsor: Zealand Pharma

Target Recruit Count: 12

Registration Number: NCT04991311

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Phase 3

Conditions: Short Bowel Syndrome

Interventions: Drug: Glepaglutide

First Posted Date: 2021-05-11

Last Posted Date: 2023-11-27

Lead Sponsor: Zealand Pharma

Target Recruit Count: 129

Registration Number: NCT04881825

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
🇩🇪
Universitätsklinikum Frankfurt, Frankfurt, Germany

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy